A top Trump administration official revealed a potential flaw in the plan to use most-favored nation deals for drug pricing, suggesting it aims to raise prices abroad rather than lower them in the U.S., which could be ineffective if the policy's term expires before impacting international markets. This highlights challenges in implementing such policies and underscores the importance of timing and political stability for content creators covering healthcare policy.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
15
Comments
Ali NematiWritten by Ali
